A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
This study is investigating a new treatment approach for head and neck cancer that has recurred (come back) or become metastatic (spread to other parts of the body). It's specifically for those whose cancer has tested negative for human papillomavirus (HPV). The trial combines a new medicine called ficlatuzumab with an existing treatment, cetuximab. Researchers want to compare this new combination to cetuximab given with a placebo (a dummy drug). They hope to find out if ficlatuzumab, when added to cetuximab, can help people live longer or stop their cancer from growing for a longer period. This research is for people who have already tried other treatments, including certain immunotherapy and chemotherapy, that didn't work or caused too many problems.
At a glance
What is this study about?
This research study, called a Phase 3 clinical trial, is looking into a new way to treat certain head and neck cancers. Specifically, it's for people whose head and neck cancer has returned or spread to other parts of the body, and whose cancer is not linked to the human papillomavirus (HPV). These types of cancers can be challenging to treat, especially if previous treatments like immunotherapy and platinum-based chemotherapy haven't been effective or if the side effects were too much to handle.
The main goal of this study is to see if adding a new drug called ficlatuzumab to an existing cancer treatment, cetuximab, is more helpful than giving cetuximab with a placebo (a substance with no medicine in it). The researchers want to know if the combination of ficlatuzumab and cetuximab can stop the cancer from growing for a longer time or help people live longer compared to just cetuximab with a placebo. By carefully studying these treatments, scientists hope to find better options for people facing this type of cancer.
About 410 people are expected to take part in this study across different locations. Participants will be randomly assigned to one of three groups: two groups will receive ficlatuzumab plus cetuximab (at different dose levels), and one group will receive a placebo plus cetuximab. This helps ensure the study results are fair and reliable. The study is "double-blind," meaning neither the participants nor their doctors will know which treatment group they are in, which also helps to keep the results unbiased.
Key takeaways
- This study evaluates a new combination treatment for HPV-negative head and neck cancer.
- It's for people whose cancer has returned or spread, and who have tried other treatments.
- The new combination includes ficlatuzumab and an existing drug, cetuximab.
- The study compares the new combination to cetuximab plus a placebo.
- It aims to see if the new combination can help people live longer or stop cancer growth.
- Participation involves regular clinic visits, infusions, blood tests, and scans.
Who may be eligible?
To be able to join this study, there are certain requirements that you would need to meet. You must be at least 18 years old and have a confirmed diagnosis of head and neck cancer that has either come back or spread to other parts of your body. If your cancer is in the throat area (oropharyngeal cancer), it needs to have tested negative for HPV. Doctors must be able to measure your cancer using scans like CT or MRI, and your cancer must be considered impossible to remove with surgery or to cure with current treatments.
You should also have already tried certain other treatments, such as immunotherapy (like anti-PD-1/PD-L1 drugs) and chemotherapy that contains platinum, and these treatments must have stopped working or caused too many side effects. Your general health and ability to perform daily activities, as measured by something called an ECOG score, should be good, and you should be expected to live for at least 12 weeks. If you are a woman who could become pregnant, you'll need to have a negative pregnancy test and agree to use effective birth control throughout the study and for 5 months afterward. Men whose partners could become pregnant also need to agree to use effective birth control.
There are also reasons why you might not be able to join. For example, if you've already had more than two previous lines of cancer treatment, or if you've been treated with cetuximab or similar drugs before, you wouldn't be eligible. The study team will review all your medical information carefully to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 or older?
- Do you have head and neck cancer that has come back or spread, and is HPV-negative?
- Have you already tried certain types of immunotherapy and platinum-based chemotherapy?
- Is your general health reasonably good, and is your cancer considered inoperable/incurable?
- Are you able to use effective birth control if you or your partner could become pregnant?
- Have you received two or fewer types of cancer treatment before this?
What does participation involve?
If you decide to take part in this study, you'll be randomly assigned to one of three treatment groups by chance, like flipping a coin. You might receive ficlatuzumab plus cetuximab, or a placebo plus cetuximab. Neither you nor your doctor will know which treatment you are receiving. The study involves regular visits to the clinic for treatments, which are given as infusions (into a vein). You will also have regular tests, including blood tests and scans like CT or MRI, to check how your body is responding to the treatment and to monitor for any side effects. You'll continue with the treatment for as long as it's helping and you're not experiencing too many side effects. After stopping treatment, there will be follow-up appointments to monitor your health. The total time you're involved in the study will depend on how you respond to the treatment and the follow-up schedule designed by the researchers.
Potential risks and benefits
Locations (112)
- Banner MD Anderson Cancer CenterVerified postcodeGilbert, United States· Recruiting
- The University of Arizona Cancer CenterVerified postcodeTucson, United States· Recruiting
- University of California Los AngelesVerified postcodeLos Angeles, United States· Recruiting
- Yale School of Medicine - Smilow Cancer HospitalVerified postcodeNew Haven, United States· Recruiting
- The George Washington UniversityVerified postcodeWashington D.C., United States· Recruiting
- AdventHealth Medical Group Oncology & Hematology at OrlandoVerified postcodeOrlando, United States· Recruiting
- Moffitt Cancer CenterVerified postcodeTampa, United States· Recruiting
- Emory UniversityVerified postcodeAtlanta, United States· Recruiting
- University of Illinois Cancer CenterVerified postcodeChicago, United States· Recruiting
- University of Kansas Cancer CenterVerified postcodeWestwood, United States· Recruiting
- Mary Bird Perkins Cancer CenterVerified postcodeBaton Rouge, United States· Recruiting
- MaineHealth Institute for ResearchVerified postcodeSouth Portland, United States· Recruiting
Common questions
What is HPV-negative head and neck cancer?
This is a type of head and neck cancer that is not caused by the human papillomavirus (HPV). Its causes and how it behaves can be different from HPV-positive cancers.
What is a Phase 3 study?
A Phase 3 study is a large research trial that compares a new treatment to existing standard treatments or a placebo to see if it's safe and effective. It's often the last step before a new treatment might become widely available.
What is a placebo?
A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active drug. It helps researchers fairly test if the new medicine is actually working.
What does 'recurrent or metastatic' mean?
Recurrent means the cancer has come back after treatment. Metastatic means the cancer has spread from where it started to other parts of the body.
Will I know if I'm getting the new drug?
No, this is a 'double-blind' study, meaning neither you nor your doctors will know if you're receiving ficlatuzumab or the placebo, to keep the study fair and unbiased.
How to find out more
Clinical Trials Office
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.